Hey Led, 

imo I would think that the clinical steering committee assuming the adjustments are not dramatic that it will be rubber stamped , Rvx IMO is extremely undervalued for a company nearly 2/3 finished a cvd trial , we should be trading near esperion therapeutics market cap, I complete failure from management to get a proper valuation, I can only imagine where we would be trading if we had a Nasdaq listing, 10 times the capital available and 10 times the investors available , let's hope for a positive FA in the next few weeks